Proactiveinvestors USA & Canada Verona Pharma https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Verona Pharma RSS feed en Sat, 15 Jun 2019 21:49:30 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7631112-en/ Tue, 04 Jun 2019 02:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7631112-en/ <![CDATA[RNS press release - Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7629088-en/ Thu, 30 May 2019 02:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7629088-en/ <![CDATA[RNS press release - PDMR Dealing ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20190529110708_14090837/ Wed, 29 May 2019 06:07:08 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20190529110708_14090837/ <![CDATA[RNS press release - Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7624205-en/ Mon, 20 May 2019 10:15:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7624205-en/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7616774-en/ Tue, 07 May 2019 07:51:41 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7616774-en/ <![CDATA[RNS press release - Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7616458-en/ Tue, 07 May 2019 02:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7616458-en/ <![CDATA[RNS press release - Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7614180-en/ Thu, 02 May 2019 07:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7614180-en/ <![CDATA[RNS press release - Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7613362-en/ Wed, 01 May 2019 02:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7613362-en/ <![CDATA[RNS press release - Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019 ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7590066-en/ Thu, 25 Apr 2019 07:07:22 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7590066-en/ <![CDATA[RNS press release - Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7581013-en/ Tue, 09 Apr 2019 02:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7581013-en/ <![CDATA[RNS press release - Grant of Options and RSUs and PDMR Dealings ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7579934-en/ Thu, 04 Apr 2019 02:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7579934-en/ <![CDATA[RNS press release - Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7564453-en/ Tue, 26 Mar 2019 03:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7564453-en/ <![CDATA[RNS press release - PDMR Dealing ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7563656-en/ Mon, 25 Mar 2019 03:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7563656-en/ <![CDATA[RNS press release - 2018 Annual Report and Accounts and Notice of AGM  ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7563273-en/ Fri, 22 Mar 2019 12:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7563273-en/ <![CDATA[RNS press release - Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7562408-en/ Thu, 21 Mar 2019 03:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7562408-en/ <![CDATA[RNS press release - PDMR Dealing ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7561369-en/ Wed, 20 Mar 2019 03:00:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7561369-en/ <![CDATA[RNS press release - PDMR Dealing ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7557050-en/ Mon, 11 Mar 2019 05:48:25 -0400 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7557050-en/ <![CDATA[RNS press release - PDMR Dealing ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7555353-en/ Thu, 07 Mar 2019 03:14:16 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7555353-en/ <![CDATA[RNS press release - PDMR Dealing ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7553863-en/ Tue, 05 Mar 2019 04:48:55 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7553863-en/ <![CDATA[RNS press release - Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7552906-en/ Mon, 04 Mar 2019 02:00:00 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7552906-en/ <![CDATA[RNS press release - Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7551119-en/ Thu, 28 Feb 2019 02:00:00 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7551119-en/ <![CDATA[RNS press release - Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7549221-en/ Tue, 26 Feb 2019 02:00:00 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7549221-en/ <![CDATA[RNS press release - Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7525760-en/ Wed, 20 Feb 2019 02:00:00 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7525760-en/ <![CDATA[RNS press release - Verona Pharma to Present at Upcoming Investor Conferences ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7497065-en/ Mon, 04 Feb 2019 02:00:00 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7497065-en/ <![CDATA[RNS press release - Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7477049-en/ Mon, 14 Jan 2019 02:00:00 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7477049-en/ <![CDATA[RNS press release - Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554 ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7475230-en/ Wed, 09 Jan 2019 08:00:00 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7475230-en/ <![CDATA[RNS press release - Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7467123-en/ Mon, 17 Dec 2018 12:20:38 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7467123-en/ <![CDATA[RNS press release - Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD ]]> https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7466748-en/ Mon, 17 Dec 2018 02:00:00 -0500 https://www.proactiveinvestors.com/companies/rns/1059/NASDAQ_7466748-en/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20180302164028_13553555/ Fri, 02 Mar 2018 11:40:28 -0500 https://www.proactiveinvestors.com/companies/rns/1059/LSE20180302164028_13553555/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20180302163515_13553550/ Fri, 02 Mar 2018 11:35:15 -0500 https://www.proactiveinvestors.com/companies/rns/1059/LSE20180302163515_13553550/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170530070012_13241445/ Tue, 30 May 2017 02:00:12 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170530070012_13241445/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170525172745_13239107/ Thu, 25 May 2017 12:27:45 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170525172745_13239107/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170523084429_13235077/ Tue, 23 May 2017 03:44:29 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170523084429_13235077/ <![CDATA[RNS press release - Partial Exercise of Over-Allotment Option ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170516074404_13226705/ Tue, 16 May 2017 02:44:04 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170516074404_13226705/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170509153646_13219637/ Tue, 09 May 2017 10:36:46 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170509153646_13219637/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170508173308_13218178/ Mon, 08 May 2017 12:33:08 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170508173308_13218178/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170505153222_13216490/ Fri, 05 May 2017 10:32:22 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170505153222_13216490/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170505121518_13216186/ Fri, 05 May 2017 07:15:18 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170505121518_13216186/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170505113614_13216084/ Fri, 05 May 2017 06:36:14 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170505113614_13216084/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170503180208_13213374/ Wed, 03 May 2017 13:02:08 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170503180208_13213374/ <![CDATA[RNS press release - Block Listing Application and Review ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170503144900_13213089/ Wed, 03 May 2017 09:49:00 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170503144900_13213089/ <![CDATA[RNS press release - Grant of Options and RSUs and PDMR Dealings ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170503123418_13212882/ Wed, 03 May 2017 07:34:18 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170503123418_13212882/ <![CDATA[RNS press release - Closing of Global Offering and Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170502181017_13211703/ Tue, 02 May 2017 13:10:17 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170502181017_13211703/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170502070019_13209868/ Tue, 02 May 2017 02:00:19 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170502070019_13209868/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170428174031_13209449/ Fri, 28 Apr 2017 12:40:31 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170428174031_13209449/ <![CDATA[RNS press release - Pricing of Offering and Approval to List on NASDAQ ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170427070016_13206106/ Thu, 27 Apr 2017 02:00:16 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170427070016_13206106/ <![CDATA[RNS press release - Global Offering and Application to List on NASDAQ ]]> https://www.proactiveinvestors.com/companies/rns/1059/LSE20170419070009_13196325/ Wed, 19 Apr 2017 02:00:09 -0400 https://www.proactiveinvestors.com/companies/rns/1059/LSE20170419070009_13196325/ <![CDATA[News - NASDAQ listing for Verona Pharma? ]]> https://www.proactiveinvestors.com/companies/news/127288/nasdaq-listing-for-verona-pharma-127288.html A NASDAQ listing was on the cards for Verona Pharma Plc (LON:VRP) as shares rose more than 20% after an oversubscribed placing raised £44.7mln to fund the development of its lung disease treatment.

The proceeds will fund the group’s RPL554 drug through a Phase 2b clinical trial in chronic obstructive pulmonary disease patients (COPD) and additional phase 2 studies in both COPD and cystic fibrosis.

The funding enables the group to materially advance the development of the drug and build on the significant progress made with the revised formulation, it said.

Verona also announced that it was pursuing “commercially reasonable efforts” to obtain a listing on NASDAQ and raise a further tranche of funding in the future.

Non-executive chairman David Ebsworth said that a NASDAQ listing was a “natural evolution” in the group’s corporate strategy to focus on the US market.

“It will also allow the company easier access to a larger pool of investors in the US who have a deep understanding of the healthcare market in which Verona Pharma operates,” said Ebsworth.

Chronic obstructive pulmonary disease is a debilitating lung disease that affects around 65mln people worldwide and is still among the four leading causes of death globally.

“We have made significant clinical progress with our first-in-class drug RPL554. This drug has shown the potential to become an important novel and complementary treatment option for patients with COPD,” said chief executive Jan-Anders Karlsson.

For the first time, the group will also explore the use of the RPL554 drug as a treatment for patients with cystic fibrosis, where it said there remained a significant unmet need.

Cornerstone investors in the placing included a number of specialist US, UK and European healthcare funds, Vivo Capital, OrbiMed and Edmond de Rothschild Investment Partners.

Verona’s lead drug RPL554 is a muscle relaxant which eases breathing and has anti-inflammatory properties. It has the potential to become a novel treatment for patients with obstructive lung diseases.

Shares rose almost 24% to 3.5p.

--UPDATE SHARE PRICE--

 

]]>
Mon, 20 Jun 2016 09:34:00 -0400 https://www.proactiveinvestors.com/companies/news/127288/nasdaq-listing-for-verona-pharma-127288.html
<![CDATA[News - Verona Pharma shares edge lower on clinical trial results ]]> https://www.proactiveinvestors.com/companies/news/45592/verona-pharma-shares-edge-lower-on-clinical-trial-results-54400.html Verona Pharma (LON:VRP) today revealed results of an exploratory clinical trial for a potential treatment of asthma and chronic obstructive pulmonary disease (COPD).

The study narrowly missed its primary endpoint objective, which was to reduce the numbers of inflammatory cells, called neutrophil cells, which play a central role in COPD and asthma.

According to Verona while the results fell short of ‘statistical significance’ there was a strong trend towards the primary end point and there was a ‘highly significant’ reduction in the absolute number of neutrophils.

It also said that there were also ‘statistically highly significant’ reductions in various types of inflammatory cells entering the airways in treated subjects; according to Verona, this provides positive evidence of the drug's anti-inflammatory effects.

The drug, tagged RPL554, is in nebulised form and it is being developed as a bronchodilator to treat patients with severe COPD.

Previous clinical trials conducted by the company have demonstrated that RPL554 is a potent bronchodilator with fast onset of action in both COPD and asthma patients.

The company now plans to focus the development of RPL554 on its bronchodilator properties in more severe patients.

"We are very excited by the outcome of this trial,” said chief executive Jan-Anders Karlsson.

“The demonstration of significant anti-inflammatory activity with RPL554, coupled with its pronounced bronchodilator effects, makes this a unique drug with significant promise as a new treatment for patients with COPD or asthma.

“Our near-term focus for the further development of RPL554 is on exploring the drug's significant bronchodilator properties in treating airway obstruction in patients with severe COPD, a disease with a significant unmet medical need.

“This promises to be the fastest way to bring RPL554 to market."

In the trial healthy subjects were treated after they inhaled an irritant. The study showed the drug to be well tolerated, and Verona said the adverse effects were mild and not significantly different to placebo.

On AIM Verona Pharma shares were down almost 2%, trading at 2.76p each.

 

 

 

 

]]>
Tue, 05 Mar 2013 09:38:00 -0500 https://www.proactiveinvestors.com/companies/news/45592/verona-pharma-shares-edge-lower-on-clinical-trial-results-54400.html
<![CDATA[News - Verona Pharma to start clinical trials on COPD drug in UK within months ]]> https://www.proactiveinvestors.com/companies/news/33586/verona-pharma-to-start-clinical-trials-on-copd-drug-in-uk-within-months-40025.html Respiratory disease specialists Verona Pharma (LON:VRP) plans to start clinical trials of its drug RPL554 to treat COPD within the next couple of months, it said.

The company has contracted the Medicines Evaluation Unit in Manchester to carry out the phase II anti-inflammatory trial - the first study in the UK.

The enrollment of patients is to start in the second quarter and the preliminary results are expected early in Q4 this year, the company said.

COPD or chronic obstructive pulmonary disease causes a narrowing of the airways in the lungs, causing shortness of breath.

The trial, being led by Professor Dave Singh, will see healthy volunteers having their airways exposed to an inflammatory stimulus.

They will then be treated using six repeated daily doses of RPL554 with an inhaler, with the primary endpoint being the reduction of inflammation.

Verona's chief executive Michael Walker said: "The fundraising completed in January this year has enabled us to initiate this important trial to show that RPL554 is anti-inflammatory.

"We have already demonstrated that this drug is a bronchodilator, i.e. dilates the airways, enabling patients to breathe more easily. If we can demonstrate there is also a combined anti-inflammatory action, this would place RPL554 in a completely new class of therapy for COPD
and asthma sufferers."

He added: "Our objective continues to be to appoint a partner to develop RPL554 into a marketed medicine. The results from this trial will provide further useful and important data for this purpose".

This clinical trial follows earlier work to test the anti-inflammatory actions of RPL554, including preclinical studies and a pilot nasal study in humans performed as part of the initial Phase I/IIa clinical trial of the drug, the company added.

]]>
Fri, 09 Mar 2012 08:04:00 -0500 https://www.proactiveinvestors.com/companies/news/33586/verona-pharma-to-start-clinical-trials-on-copd-drug-in-uk-within-months-40025.html